On a Stepwise Quantitative Approach for Benefit-Risk Assessment.

Area of Science:

• Pharmacovigilance and Drug Safety
• Regulatory Science
• Health Economics and Outcomes Research

Background:

• Structured benefit-risk assessment is crucial for drug evaluation and has seen significant regulatory and industry advancements.
• Existing approaches share common elements but lack specific guidance on metrics and methods.
• Benefit-risk assessment requires tailored metrics and analysis methods for individual clinical contexts.

Purpose of the Study:

• To propose a generalizable, stepwise quantitative approach for benefit-risk assessment.
• To provide guidance on metrics and methods applicable across different clinical settings.
• To demonstrate the utility of the proposed approach through real-world case studies.

Main Methods:

• Development of a stepwise quantitative framework for benefit-risk assessment.
• Identification of common elements and principles across existing structured approaches.
• Application and validation of the proposed approach using three distinct case studies.

Main Results:

• A systematic, stepwise quantitative methodology for benefit-risk assessment was successfully developed.
• The approach provides a flexible yet structured framework for evaluating drug benefits against risks.
• Case study applications demonstrated the practical utility and adaptability of the proposed method.

Conclusions:

• The proposed stepwise quantitative approach offers a valuable framework for conducting structured benefit-risk assessments.
• Generalizable principles for benefit-risk metrics and methods can be effectively applied across diverse clinical scenarios.
• This approach can enhance consistency and transparency in regulatory decision-making regarding drug safety and efficacy.